Literature DB >> 20082061

[Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

C Lichtenstern1, S Swoboda, M Hirschburger, E Domann, T Hoppe-Tichy, M Winkler, C Lass-Flörl, M A Weigand.   

Abstract

Fungal infections are of great relevance in surgical intensive care and Candida species represent the predominant part of fungal pathogens. Invasive aspergillosis is also relevant especially in patients with chronic pulmonary diseases. It is crucial for therapy success to begin adequate antifungal treatment at an early stage of the disease. Risk stratification of individual patient symptoms is essential for therapy timing. In case of suspected or proven candida infection, fluconazole is the agent of choice when the patient is clinically stable and no azoles have been administrated in advance and the local epidemiology makes azol resistance unlikely. For clinically instable patients with organ dysfunction the echinocandins serve as primary therapy because of their broad spectrum and reasonable safety profile. Due to a relevant proportion of azole resistant Candida species, susceptibility testing should be done routinely. Depending on the species detected de-escalating to an azole is feasible if organ dysfunctions have resolved. An invasive aspergillosis is primarily treated with voriconazole.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20082061     DOI: 10.1007/s00101-009-1655-4

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  179 in total

Review 1.  Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis.

Authors:  Monique A S H Mennink-Kersten; J Peter Donnelly; Paul E Verweij
Journal:  Lancet Infect Dis       Date:  2004-06       Impact factor: 25.071

2.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

Review 3.  Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature.

Authors:  E J Anaissie; R O Darouiche; D Abi-Said; O Uzun; J Mera; L O Gentry; T Williams; D P Kontoyiannis; C L Karl; G P Bodey
Journal:  Clin Infect Dis       Date:  1996-11       Impact factor: 9.079

4.  Effects of nosocomial candidemia on outcomes of critically ill patients.

Authors:  Stijn I Blot; Koenraad H Vandewoude; Eric A Hoste; Francis A Colardyn
Journal:  Am J Med       Date:  2002-10-15       Impact factor: 4.965

5.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

6.  Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis.

Authors:  D P Kontoyiannis; V Ratanatharathorn; J-A Young; J Raymond; M Laverdière; D W Denning; T F Patterson; D Facklam; L Kovanda; L Arnold; W Lau; D Buell; K A Marr
Journal:  Transpl Infect Dis       Date:  2008-10-08       Impact factor: 2.228

Review 7.  Current status of nonculture methods for diagnosis of invasive fungal infections.

Authors:  Siew Fah Yeo; Brian Wong
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

8.  A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

Authors:  Peter G Pappas; John H Rex; Jeannette Lee; Richard J Hamill; Robert A Larsen; William Powderly; Carol A Kauffman; Newton Hyslop; Julie E Mangino; Stanley Chapman; Harold W Horowitz; John E Edwards; William E Dismukes
Journal:  Clin Infect Dis       Date:  2003-08-14       Impact factor: 9.079

9.  A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

Authors:  John H Rex; Peter G Pappas; Adolf W Karchmer; Jack Sobel; John E Edwards; Susan Hadley; Corstiaan Brass; Jose A Vazquez; Stanley W Chapman; Harold W Horowitz; Marcus Zervos; David McKinsey; Jeannette Lee; Timothy Babinchak; Robert W Bradsher; John D Cleary; David M Cohen; Larry Danziger; Mitchell Goldman; Jesse Goodman; Eileen Hilton; Newton E Hyslop; Daniel H Kett; Jon Lutz; Robert H Rubin; W Michael Scheld; Mindy Schuster; Bryan Simmons; David K Stein; Ronald G Washburn; Linda Mautner; Teng-Chiao Chu; Helene Panzer; Rebecca B Rosenstein; Jenia Booth
Journal:  Clin Infect Dis       Date:  2003-05-08       Impact factor: 9.079

10.  Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.

Authors:  Bart J Rijnders; Jan J Cornelissen; Lennert Slobbe; Martin J Becker; Jeanette K Doorduijn; Wim C J Hop; Elisabeth J Ruijgrok; Bob Löwenberg; Arnold Vulto; Pieternella J Lugtenburg; Siem de Marie
Journal:  Clin Infect Dis       Date:  2008-05-01       Impact factor: 9.079

View more
  2 in total

1.  [Candiduria! What now? : Therapy of urinary tract infections with Candida].

Authors:  H Hof
Journal:  Urologe A       Date:  2017-02       Impact factor: 0.639

2.  Antifungal therapy in patients with pulmonary Candida spp. colonization may have no beneficial effects.

Authors:  Simone Lindau; Manuel Nadermann; Hanns Ackermann; Tobias Michael Bingold; Christoph Stephan; Volkhard A J Kempf; Pia Herzberger; Andres Beiras-Fernandez; Kai Zacharowski; Patrick Meybohm
Journal:  J Intensive Care       Date:  2015-07-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.